[Distribution characteristics of serum HBsAg levels in Chinese patients with chronic hepatitis B based on CR-HepB]
Related Experiment Video
Updated: Jul 12, 2026
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing 100050, China.
Insights
This study shows that serum hepatitis B surface antigen (HBsAg) levels decrease over time with antiviral treatment in chronic hepatitis B (CHB) patients. Longer treatment duration correlates with lower HBsAg levels, particularly in older patients.
Area of Science:
- Hepatology
- Virology
- Public Health
Abstract:
Objective: To explore the distribution characteristics of HBsAg levels in treatment-naïve and treatment-experienced patients with chronic hepatitis B (CHB) in China. Methods: Data were obtained from the China Registry of Hepatitis B (CR-HepB) platform from the establishment of the platform to April 11, 2024. Patients with CHB who were treatment-naïve and treatment-experienced with nucleos(t)ide analogs (NAs) were included. Relevant clinical data were collected. The distribution of hepatitis B surface antigen (HBsAg) status, as well as the levels in populations of different age groups after different antiviral treatment durations, were retrospectively analyzed. Normally and non-normally distributed measured data were represented by Mean±SD, and M(Q1, Q3). Results: A total of 13 505 treatment-naïve patients and 6 390 treatment-experienced patients were included in the analysis. The proportions of treatment-naïve patients with HBsAg<100, <500, and <1 500 IU/mL were 10.51%, 28.47%, and 46.85%, and the corresponding proportions of treatment-experienced patients were 12.88%, 29.84%, and 52.07%. The proportions of treatment-naïve patients with HBsAg levels≥1 500, ≥3 000, and≥8 000 IU/mL were 53.15%, 38.17%, and 15.62%, and the corresponding proportions of treatment-experienced patients were 47.93%, 31.77%, and 10.39%. HBsAg level showed a trend of gradual decrease with the increase of antiviral treatment time. The proportion of treatment-experienced patients with HBsAg<100 IU/mL increased from 12.73% when the treatment duration was less than three years to 26.92% when the treatment duration was≥10 years, while the proportion of patients with HBsAg levels≥3 000 IU/mL or≥8 000 IU/mL decreased from 34.66% to 23.08% and from 12.19% to 5.77%, respectively. The proportion of patients with HBsAg<100, <500, and<1 500 IU/mL increased with age, while the proportion of patients with HBsAg≥1 500, ≥3 000, and ≥8 000 IU/mL decreased sequentially. Conclusions: The CR-HepB platform provides a basis for clarifying the serum HBsAg levels in treatment-naïve and treatment-experienced CHB patients in China. The HBsAg status indicates that with a prolonged antiviral treatment duration, there is a gradual decline trend in HBsAg level.
